{"title":"A framework of biomarkers for skeletal aging: a consensus statement by the Aging Biomarker Consortium","authors":"Jinlong Suo, Yibo Gan, Yangli Xie, Shuqin Xu, Jianfang Wang, Di Chen, Lin Chen, Lianfu Deng, Shiqing Feng, Jingdong Jackie Han, Qing Jiang, Guanghua Lei, Peng Liu, Xianghang Luo, Xin Ma, Jing Qu, Chunli Song, P. Tang, Tingting Tang, Sijia Wang, Xiaochun Wei, Chengtie Wu, Guozhi Xiao, Liu Yang, Licheng Zhang, Weiqi Zhang, Zhenlin Zhang, Guanghui Liu, Changqing Zhang, Gang Pei, Jian Luo, Rui Yue, Weiguo Zou","doi":"10.1093/lifemedi/lnad045","DOIUrl":null,"url":null,"abstract":"The skeleton is an important structural and metabolic organ in human body, while aging is the physiological basis for degenerative skeletal diseases. China has the largest aging population in the world and faces great challenges in preventing and managing diseases related to skeletal aging. To address these challenges, the Aging China Biomarkers Consortium (ABC) has reached an expert consensus on biomarkers of skeletal aging by synthesizing the literature and insights from scientists and clinicians. The consensus provides a comprehensive assessment of biomarkers associated with skeletal aging and proposes a systematic framework that categorizes biomarkers into three dimensions, namely, functional, structural, and humoral dimensions. Within each dimension, the ABC recommended clinical and evidential research-based biomarkers for physiological aging and degenerative pathologies of the skeleton. This expert consensus aims to lay the foundation for future studies to assess the prediction, diagnosis, early warning and treatment of diseases associated with skeletal aging, with the ultimate goal of improving the skeletal health of elderly populations in China and around the world.","PeriodicalId":74073,"journal":{"name":"Life medicine","volume":"65 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/lifemedi/lnad045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The skeleton is an important structural and metabolic organ in human body, while aging is the physiological basis for degenerative skeletal diseases. China has the largest aging population in the world and faces great challenges in preventing and managing diseases related to skeletal aging. To address these challenges, the Aging China Biomarkers Consortium (ABC) has reached an expert consensus on biomarkers of skeletal aging by synthesizing the literature and insights from scientists and clinicians. The consensus provides a comprehensive assessment of biomarkers associated with skeletal aging and proposes a systematic framework that categorizes biomarkers into three dimensions, namely, functional, structural, and humoral dimensions. Within each dimension, the ABC recommended clinical and evidential research-based biomarkers for physiological aging and degenerative pathologies of the skeleton. This expert consensus aims to lay the foundation for future studies to assess the prediction, diagnosis, early warning and treatment of diseases associated with skeletal aging, with the ultimate goal of improving the skeletal health of elderly populations in China and around the world.
骨骼是人体重要的结构和代谢器官，而衰老是骨骼退行性疾病的生理基础。中国是世界上老龄人口最多的国家，在预防和管理骨骼衰老相关疾病方面面临着巨大挑战。为了应对这些挑战，"老龄化中国生物标志物联盟"（Aging China Biomarkers Consortium，ABC）通过综合文献以及科学家和临床医生的见解，就骨骼衰老的生物标志物达成了专家共识。该共识对与骨骼衰老相关的生物标志物进行了全面评估，并提出了一个系统框架，将生物标志物分为三个维度，即功能、结构和体液维度。在每个维度中，ABC 推荐了基于临床和证据研究的生物标志物，用于检测骨骼的生理衰老和退行性病变。该专家共识旨在为未来研究评估骨骼衰老相关疾病的预测、诊断、预警和治疗奠定基础，最终目标是改善中国乃至全球老年人群的骨骼健康状况。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
